My take on the standing ovation for DESTINY Breast 04
Traztuzumab Deruxtecan vs. Investigator choice after endocrine therapy and 1 or 2 chemotherapies for HER2 low
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
This website doesn't track the visitors or use any cookies. Made by Alex Barredo. Send your feedback to alex@barredo.es.
